Trastuzumab in HER2-positive Biliary Tract Cancer

Summary

Trastuzumab is approved for the treatment of HER2-positive breast cancer and gastric cancer. The recent study showed that HER2 overexpression or amplification is noted about 5-15% of total biliary tract cancer patients. The aim of this study is to evaluate the efficacy and safety of trastuzumab in the combination of current standard gemcitabine plus cisplatin.

Timeline

Start

2019-06-01

Primary completion

2020-11-01

Completion

2021-01-04

Drugs

Indications